strefen 8,75 mg 16 píndoles per a llepar mel i llimona
strefen spray 8.75 mg/dosi solució pulverització bucal 15 ml
strefen 8,75 mg 16 píndoles per a llepar taronja
cholestagel 625 mg 180 comprimits recoberts
بيكالوتاميد تيڤع ١٥٠ ملغ
teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.
بيكالوتاميد تيڤع ٥٠ ملغ
teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.
ميرتازاپين تيڤع ۳٠ ملغ
teva pharmaceutical indust.ltd - mirtazapine 30 mg - tablets - mirtazapine - episode of major depression.
ايلاترولت
teva pharmaceutical indust.ltd - amitriptyline hydrochloride 10 mg - tablets - amitriptyline - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. enuresis nocturna.
اوفلوكساسين تيڤع ٢٠٠ ملغ
abic ltd. - ofloxacin 200 mg - tablets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).